Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TELO Telomir Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: TELO
Price (delayed)
$2.11
Market cap
$62.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.42
Enterprise value
$62.4M
We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for
Highlights
Telomir Pharmaceuticals's EPS has increased by 39% YoY and by 25% QoQ
The company's net income rose by 34% YoY and by 24% QoQ
Telomir Pharmaceuticals's equity has shrunk by 125% QoQ and by 105% YoY
The quick ratio has plunged by 91% YoY and by 67% from the previous quarter
Key stats
What are the main financial stats of TELO
Market
Valuations
Earnings
Shares outstanding
29.76M
Market cap
$62.8M
Enterprise value
$62.4M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$12.57M
Net income
-$12.52M
EBIT
-$12.53M
EBITDA
-$12.53M
Free cash flow
-$3.99M
Per share
Balance sheet
Liquidity
EPS
-$0.42
EPS diluted
-$0.42
Free cash flow per share
-$0.13
Book value per share
-$0.01
Revenue per share
$0
TBVPS
$0.02
Total assets
$491,188
Total liabilities
$652,294
Debt
$0
Equity
-$161,106
Working capital
-$161,106
Debt to equity
0
Current ratio
0.75
Quick ratio
0.62
Net debt/EBITDA
0.03
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-1,009.7%
Return on equity
-2,009.6%
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TELO stock price
How has the Telomir Pharmaceuticals stock price performed over time
Intraday
3.43%
1 week
1.93%
1 month
-18.53%
1 year
-60.04%
YTD
-48.79%
QTD
-34.67%
Financial performance
How have Telomir Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.57M
Net income
-$12.52M
Gross margin
N/A
Net margin
N/A
TELO's operating income has dropped by 134% year-on-year and by 2.7% since the previous quarter
The company's net income rose by 34% YoY and by 24% QoQ
Price vs fundamentals
How does TELO's price correlate with its fundamentals
Growth
What is Telomir Pharmaceuticals's growth rate over time
Valuation
What is Telomir Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Telomir Pharmaceuticals's EPS has increased by 39% YoY and by 25% QoQ
Telomir Pharmaceuticals's equity has shrunk by 125% QoQ and by 105% YoY
Efficiency
How efficient is Telomir Pharmaceuticals business performance
The return on assets has dropped by 88% year-on-year and by 22% since the previous quarter
The ROE has plunged by 72% from the previous quarter
Dividends
What is TELO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TELO.
Financial health
How did Telomir Pharmaceuticals financials performed over time
The total assets is 25% smaller than the total liabilities
The quick ratio has plunged by 91% YoY and by 67% from the previous quarter
TELO's current ratio has plunged by 90% YoY and by 61% from the previous quarter
Telomir Pharmaceuticals's debt is 100% more than its equity
Telomir Pharmaceuticals's equity has shrunk by 125% QoQ and by 105% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.